跳至內容

組織蛋白酶D

本頁使用了標題或全文手工轉換
維基百科，自由的百科全書
組織蛋白酶D
已知的結構
PDB直系同源搜尋: PDBe RCSB
識別號
別名CTSD；, CLN10, CPSD, HEL-S-130P, cathepsin D
外部IDOMIM：116840 MGI：88562 HomoloGene：55616 GeneCards：CTSD
相關疾病
neuronal ceroid lipofuscinosis 10、​神經元蠟樣脂褐質儲積症[1]
基因位置（人類）
11號染色體
染色體11號染色體[2]
11號染色體
組織蛋白酶D的基因位置
組織蛋白酶D的基因位置
基因座11p15.5起始1,752,752 bp[2]
終止1,764,573 bp[2]
RNA表達模式


查閱更多表達數據
直系同源
物種人類小鼠
Entrez

1509

13033

Ensembl

ENSG00000117984

ENSMUSG00000007891

UniProt

P07339

P18242

mRNA​序列

NM_001909

NM_009983

蛋白序列

NP_001900

NP_034113

基因位置​（UCSC）Chr 11: 1.75 – 1.76 MbChr 7: 141.93 – 141.94 Mb
PubMed​查找[4][5]
維基數據
檢視/編輯人類檢視/編輯小鼠

組織蛋白酶D是一種在人體中由CTSD基因編碼的蛋白質。[6][7]該基因編碼一種溶酶體天門冬胺醯蛋白酶，該蛋白酶由二硫鍵連接的重鏈和輕鏈的蛋白二聚體組成，兩者均由單一蛋白質前體產生。組織蛋白酶D是一種天冬氨酸內切蛋白酶，廣泛分佈於溶酶體中。[8]組織蛋白酶D的主要功能是降解蛋白質並活化溶酶體前區室中生物活性蛋白的前體。[9]這種蛋白酶是肽酶A1家族的成員，具有與胃蛋白酶A相似但比胃蛋白酶A更窄的特異性。 CTSD基因的轉錄從幾個位點開始，包括一個作為雌激素調節轉錄物起始位點的位點。該基因的突變與幾種疾病的發病機制有關，包括乳腺癌和可能的阿茲海默症症。[7]CTSD基因的純合缺失導致出生後階段的早期致死性。[10]據報道，CTSD基因的缺陷是神經元蠟樣脂褐質沉積症（NCL）的根本原因。[11]

結構

基因

CTSD基因位於11號染色體。

蛋白質

組織蛋白酶D的催化位點包括位於14kDa和34kDa鏈上的兩個關鍵天冬氨酸殘基（氨基酸33和231）。[12]成熟組織蛋白酶D的最終形式由337個氨基酸殘基、196個重鏈氨基酸殘基和141個輕鏈氨基酸殘基組成。這兩條鏈通過疏水效應連接起來。[13]

功能

在體外，組織蛋白酶D的最適pH值為4.5至5.0。[14]組織蛋白酶D是一種天冬氨酸蛋白酶，它嚴重依賴於其活性位點Asp殘基的質子化。與Asp質子化一起，較低的pH 值也會導致組織蛋白酶D的構象轉換：隨着pH值的下降，蛋白酶的N端片段會移出活性位點。[15][16][17]與其他天冬氨酸蛋白酶類似，組織蛋白酶D在活性位點的結合裂隙中容納多達8個氨基酸殘基。組織蛋白酶D的主要生理功能包括細胞內蛋白質的代謝降解、多肽激素和生長因子的活化和降解、酶前體的活化、酶活化劑和抑制劑的加工、腦抗原加工和細胞程式性死亡的調節。[18][19][20][21]組織蛋白酶D也可以在細胞外空間中找到，[21]它是少數在中性pH條件下顯示出一些活性的組織蛋白酶之一。[22]它能夠活化生長因子VEGF-C和VEGF-D，這可能部分解釋了它與腫瘤進展的相關性。[23]

臨床意義

NCL表現為視覺功能的進行性喪失和神經發育衰退、癲癇發作、肌陣攣性抽搐和過早死亡。 CTSD基因是已確定的八個基因之一，其缺陷是導致NCL的原因。[11]據報告，外顯子6中的純合單核苷酸重複可以改變閱讀框並導致255位的過早終止密碼子。組織蛋白酶 D 的過表達刺激致瘤性和轉移以及腫瘤細胞凋亡的開始。這種蛋白酶被認為是乳腺癌預後不良的獨立標誌物，與臨床轉移的發生率相關。[24][25]CTSD基因敲除會導致腸壞死和出血，胸腺凋亡增加，表明某些上皮細胞需要組織蛋白酶D進行組織重塑和更新。[10]另據報告，CTSD基因型可能對男性阿茲海默症風險有強烈影響。[26]組織蛋白酶D的酶活性誘導含有載脂蛋白B-100 的脂蛋白（包括 LDL）的水解修飾，這意味着它也可能與動脈粥樣硬化有關。[19][27]

相互作用

參考文獻

  1. ^ 與组织蛋白酶D相關的疾病；在維基數據上查看/編輯參考. 
  2. ^ 2.0 2.1 2.2 GRCh38: Ensembl release 89: ENSG00000117984 - Ensembl, May 2017
  3. ^ 3.0 3.1 3.2 GRCm38: Ensembl release 89: ENSMUSG00000007891 - Ensembl, May 2017
  4. ^ Human PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine. 
  5. ^ Mouse PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine. 
  6. ^ Faust PL, Kornfeld S, Chirgwin JM. Cloning and sequence analysis of cDNA for human cathepsin D. Proceedings of the National Academy of Sciences of the United States of America. August 1985, 82 (15): 4910–4. Bibcode:1985PNAS...82.4910F. PMC 390467 可免費查閱. PMID 3927292. doi:10.1073/pnas.82.15.4910 可免費查閱. 
  7. ^ 7.0 7.1 Entrez Gene: CTSD cathepsin D. [2022-09-18]. （原始內容存檔於2010-04-12）. 
  8. ^ Barrett AJ. Cathepsin D. Purification of isoenzymes from human and chicken liver. The Biochemical Journal. April 1970, 117 (3): 601–7. PMC 1178965 可免費查閱. PMID 5419752. doi:10.1042/bj1170601. 
  9. ^ Diment S, Martin KJ, Stahl PD. Cleavage of parathyroid hormone in macrophage endosomes illustrates a novel pathway for intracellular processing of proteins. The Journal of Biological Chemistry. August 1989, 264 (23): 13403–6. PMID 2760027. doi:10.1016/S0021-9258(18)80010-2 可免費查閱. 
  10. ^ 10.0 10.1 Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H, Köster A, Hess B, Evers M, von Figura K. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. The EMBO Journal. August 1995, 14 (15): 3599–608. PMC 394433 可免費查閱. PMID 7641679. doi:10.1002/j.1460-2075.1995.tb00029.x. 
  11. ^ 11.0 11.1 Ramirez-Montealegre D, Rothberg PG, Pearce DA. Another disorder finds its gene. Brain. June 2006, 129 (Pt 6): 1353–6. PMID 16738059. doi:10.1093/brain/awl132 可免費查閱. 
  12. ^ Metcalf P, Fusek M. Two crystal structures for cathepsin D: the lysosomal targeting signal and active site. The EMBO Journal. April 1993, 12 (4): 1293–302. PMC 413340 可免費查閱. PMID 8467789. doi:10.1002/j.1460-2075.1993.tb05774.x. 
  13. ^ Minarowska A, Gacko M, Karwowska A, Minarowski Ł. Human cathepsin D. Folia Histochemica et Cytobiologica / Polish Academy of Sciences, Polish Histochemical and Cytochemical Society. 2008, 46 (1): 23–38. PMID 18296260. doi:10.2478/v10042-008-0003-x 可免費查閱. 
  14. ^ Briozzo P, Morisset M, Capony F, Rougeot C, Rochefort H. In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Research. July 1988, 48 (13): 3688–92. PMID 3378211. 
  15. ^ Authier F, Metioui M, Fabrega S, Kouach M, Briand G. Endosomal proteolysis of internalized insulin at the C-terminal region of the B chain by cathepsin D. The Journal of Biological Chemistry. March 2002, 277 (11): 9437–46. PMID 11779865. doi:10.1074/jbc.M110188200 可免費查閱. 
  16. ^ Lee AY, Gulnik SV, Erickson JW. Conformational switching in an aspartic proteinase. Nature Structural Biology. October 1998, 5 (10): 866–71 [2022-09-18]. PMID 9783744. S2CID 5685201. doi:10.1038/2306. （原始內容存檔於2022-09-22）. 
  17. ^ Petsko G, Ringe D. Protein Structure and Function. Oxford [England]; Sunderland, MA; New York: Oxford University Press. 2004. ISBN 978-1-4051-1922-1. 
  18. ^ Baechle D, Flad T, Cansier A, Steffen H, Schittek B, Tolson J, et al. Cathepsin D is present in human eccrine sweat and involved in the postsecretory processing of the antimicrobial peptide DCD-1L. The Journal of Biological Chemistry. March 2006, 281 (9): 5406–15. PMID 16354654. doi:10.1074/jbc.M504670200 可免費查閱. 
  19. ^ 19.0 19.1 Hakala JK, Oksjoki R, Laine P, Du H, Grabowski GA, Kovanen PT, Pentikäinen MO. Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions. Arteriosclerosis, Thrombosis, and Vascular Biology. August 2003, 23 (8): 1430–6. PMID 12750117. doi:10.1161/01.ATV.0000077207.49221.06 可免費查閱. 
  20. ^ Bańkowska A, Gacko M, Chyczewska E, Worowska A. Biological and diagnostic role of cathepsin D. Roczniki Akademii Medycznej W Białymstoku. 1997,. 42 Suppl 1: 79–85. PMID 9337526. 
  21. ^ 21.0 21.1 Benes P, Vetvicka V, Fusek M. Cathepsin D—many functions of one aspartic protease. Critical Reviews in Oncology/Hematology. October 2008, 68 (1): 12–28. PMC 2635020 可免費查閱. PMID 18396408. doi:10.1016/j.critrevonc.2008.02.008. 
  22. ^ Lkhider M, Castino R, Bouguyon E, Isidoro C, Ollivier-Bousquet M. Cathepsin D released by lactating rat mammary epithelial cells is involved in prolactin cleavage under physiological conditions. Journal of Cell Science. October 2004, 117 (Pt 21): 5155–64. PMID 15456852. doi:10.1242/jcs.01396 可免費查閱. 
  23. ^ Jha, Sawan Kumar; Rauniyar, Khushbu; Chronowska, Ewa; Mattonet, Kenny; Maina, Eunice Wairimu; Koistinen, Hannu; Stenman, Ulf-Håkan; Alitalo, Kari; Jeltsch, Michael. KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D. eLife. 2019-05-17, 8: –44478. ISSN 2050-084X. PMC 6588350 可免費查閱. PMID 31099754. doi:10.7554/eLife.44478. 
  24. ^ Traynor JP, Oun HA, McKenzie P, Shilliday IR, McKay IG, Dunlop A, Geddes CC, Mactier RA. Assessing the utility of the stop dialysate flow method in patients receiving haemodiafiltration. Nephrology, Dialysis, Transplantation. November 2005, 20 (11): 2479–84. PMID 16046508. doi:10.1093/ndt/gfi021 可免費查閱. 
  25. ^ Wolf M, Clark-Lewis I, Buri C, Langen H, Lis M, Mazzucchelli L. Cathepsin D specifically cleaves the chemokines macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-1 beta, and SLC that are expressed in human breast cancer. The American Journal of Pathology. April 2003, 162 (4): 1183–90. PMC 1851240 可免費查閱. PMID 12651610. doi:10.1016/S0002-9440(10)63914-4. 
  26. ^ Menzer G, Müller-Thomsen T, Meins W, Alberici A, Binetti G, Hock C, Nitsch RM, Stoppe G, Reiss J, Finckh U. Non-replication of association between cathepsin D genotype and late onset Alzheimer disease. American Journal of Medical Genetics. March 2001, 105 (2): 179–82. PMID 11304834. doi:10.1002/ajmg.1204. 
  27. ^ Haidar B, Kiss RS, Sarov-Blat L, Brunet R, Harder C, McPherson R, Marcel YL. Cathepsin D, a lysosomal protease, regulates ABCA1-mediated lipid efflux. The Journal of Biological Chemistry. December 2006, 281 (52): 39971–81. PMID 17032648. doi:10.1074/jbc.M605095200 可免費查閱. 
  28. ^ Umezawa H, Aoyagi T, Morishima H, Matsuzaki M, Hamada M. Pepstatin, a new pepsin inhibitor produced by Actinomycetes. The Journal of Antibiotics. May 1970, 23 (5): 259–62. PMID 4912600. doi:10.7164/antibiotics.23.259 可免費查閱. 
  29. ^ Kim SJ, Kim KH, Ahn ER, Yoo BC, Kim SY. Depletion of cathepsin D by transglutaminase 2 through protein cross-linking promotes cell survival. Amino Acids. January 2013, 44 (1): 73–80. PMID 21960143. S2CID 17149825. doi:10.1007/s00726-011-1089-6. 
  30. ^ Devosse T, Dutoit R, Migeotte I, De Nadai P, Imbault V, Communi D, Salmon I, Parmentier M. Processing of HEBP1 by cathepsin D gives rise to F2L, the agonist of formyl peptide receptor 3. Journal of Immunology. August 2011, 187 (3): 1475–85. PMID 21709160. doi:10.4049/jimmunol.1003545 可免費查閱. 
  31. ^ Mariani E, Seripa D, Ingegni T, Nocentini G, Mangialasche F, Ercolani S, Cherubini A, Metastasio A, Pilotto A, Senin U, Mecocci P. Interaction of CTSD and A2M polymorphisms in the risk for Alzheimer's disease. Journal of the Neurological Sciences. September 2006, 247 (2): 187–91. PMID 16784755. S2CID 34224448. doi:10.1016/j.jns.2006.05.043. 
  32. ^ Heinrich M, Wickel M, Schneider-Brachert W, Sandberg C, Gahr J, Schwandner R, Weber T, Saftig P, Peters C, Brunner J, Krönke M, Schütze S. Cathepsin D targeted by acid sphingomyelinase-derived ceramide. The EMBO Journal. October 1999, 18 (19): 5252–63. PMC 1171596 可免費查閱. PMID 10508159. doi:10.1093/emboj/18.19.5252. 

更多閱讀

外部連結

取自 "https://zh.wikipedia.org/w/index.php?title=组织蛋白酶D&oldid=78973317"